1 / 19

Surveillance & Environmental Health

West Nile Virus Seroprevalence: Results of Enhanced Surveillance Program. Surveillance & Environmental Health. Goals of the sero-survey. Compliment to regular clinical data Provides baseline infection rate and change over time Identifies risk factors of WNv infection

tavia
Download Presentation

Surveillance & Environmental Health

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. West Nile Virus Seroprevalence: Results of Enhanced Surveillance Program Surveillance & Environmental Health

  2. Goals of the sero-survey • Compliment to regular clinical data • Provides baseline infection rate and change over time • Identifies risk factors of WNv infection • Lessons learned can be transferred to new arthropod borne viruses

  3. Vectors: Mosquitoes Dead-end Hosts: Humans & other vertebrates Reservoir, Introductory & Amplifying Hosts: Birds West Nile virus Transmission Cycle

  4. Illness in Humans • Majority experience very mild or no symptoms • WNv Non-neurological Syndrome: Flu like symptoms: fever, headache, body aches, rash • WNv Neurological Syndrome: Encephalitis, meningitis, acute flaccid paralysis, often with long term effects

  5. West Nile virus history 1937: Virus first identified in the West Nile province of Uganda. 1990s: more virulent strain emerged in North Africa; outbreaks in Europe and the Middle East (e.g., Romania, Russia, Israel) 1999: WNv found in New York, USA 2000: Surveillance for WNv begins in Canada (birds, mosquitoes, humans, horses) 2001: first detected in Ontario, Canada in birds and mosquitoes 2002: human cases detected in Ontario and Quebec 2003: first human cases in MB, SK, and AB

  6. Distribution in the US: 2006

  7. National distribution 2002 Source: West Nile Virus Monitor - PHAC

  8. National distribution 2003 Source: West Nile Virus Monitor - PHAC

  9. National distribution 2004 Source: West Nile Virus Monitor - PHAC

  10. National distribution 2005 Source: West Nile Virus Monitor - PHAC

  11. National distribution 2006 Source: West Nile Virus Monitor - PHAC

  12. National distribution 2007 Source: West Nile Virus Monitor - PHAC

  13. Natural Regions Boreal Forest Canadian Shield Foothills Grassland Parkland Rocky Mountain HealthRegion Boundaries Human Cases 1 - 2 3 - 6 7 - 12 13 - 24 25 - 61 West Nile virus Geographic Distribution of Clinical Cases

  14. PURPOSE • To estimate how many Albertans have been exposed to WNv • To assess knowledge, attitudes and personal protective behaviours METHODS • Short telephone KAB survey • Blood requisition sent to participants • Blood screened in AB Provincial Lab of Microbiology, then positives confirmed at the National Lab of Microbiology in Winnipeg, MB.

  15. Blood Work

  16. Seroprevalence:

  17. Seroprevalence: 2004 • ~ 6900 Albertans infected with WNv • ~1/26 infected became clinical cases in 2003 • ~1/142 infected developed severe illness in 2003 2007 • ~34,247 Albertans infected with WNv • ~1/856 infected became clinical cases in 2006 • ~1/1631 infected developed severe illness in 2006 Note: these numbers relate to the year previous the study because we tested for seropositivity that occurred prior to the study year

  18. Conclusions • Seroprevalence appears to have increased between the two study periods • Estimates of the absolute numbers of seropositive Albertans has increased due to the occurrence of urban positive samples • The proportion of seropositive cases that became clinical appears to have reduced since the virus first appeared in the province • The proportion of seropositive cases that become clinical is very low • Future sero-surveys will be needed to corroborate these findings

  19. Contact Information Surveillance and Environmental Health Public Health Division Alberta Health and Wellness P O Box 1360 Station Main Edmonton, AB T5J 2N3 CANADA Telephone: 1.780.427.4518 Facsimile: 1.780.427.1470 E-mail: Health.Surveillance@gov.ab.ca Internet: www.health.gov.ab.ca

More Related